Developments in Intralesional Therapy for Metastatic Melanoma.
Cancer Control
; 23(1): 12-20, 2016 Jan.
Article
em En
| MEDLINE
| ID: mdl-27009452
ABSTRACT
BACKGROUND:
Locoregional advanced melanoma poses a complex clinical challenge that requires a multidisciplinary, patient-centered approach. Numerous agents have been studied for their suitability as intralesional therapy in the past decades, but few have successfully completed phase 3 clinical trial testing.METHODS:
The relevant medical literature was searched for articles regarding use of intralesional therapies in metastatic melanoma. Therapies with data from phase 2 or higher studies were selected for review. This review also summarizes the mechanisms of action, adverse-event profiles, and clinical data for these agents.RESULTS:
Intralesional therapies demonstrate promising effects in select patients with advanced melanoma. The optimal approach should be individually tailored and consist of a combination of intralesional therapies, regional perfusions, systemic immunotherapies, targeted therapies, and surgery, if necessary.CONCLUSIONS:
Due to its relatively good local response rates and tolerable adverse-event profile, intralesional therapy may be a treatment option for select patients with unresectable, locally advanced or metastatic melanoma.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Terapia Genética
/
Injeções Intralesionais
/
Vírus Oncolíticos
/
Imunoterapia
/
Melanoma
Limite:
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article